Olema Pharmaceuticals, Inc.
OLMAHeld by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Palazestrant): Jun 2026. Short interest: 20.4% of float.
Held by 11 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying11 funds opened new positions. Next phase3 readout (Palazestrant): Jun 2026. Short interest: 20.4% of float.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.